44 results
Page 2 of 3
8-K
EX-99.1
h433m
10 Aug 23
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:08pm
8-K
3sf0nrpdri
29 Jun 23
Zymeworks Appoints New Director
4:12pm
8-K
EX-10.1
oyth6t6ii0cpi 4x
18 May 23
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
8:40am
8-K
EX-10.1
c7pw0o
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
yfl0r2ai6wbq68llba0
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
l50q9ci dmlgck9imf2v
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
mbx tcfi4
8 May 23
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:13pm
10-K/A
oergu6h6nwk
28 Apr 23
Annual report (amended)
4:15pm
8-K
EX-99.1
bpm7tizknl9 e4
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
8:37am
DEF 14A
tn2x35p535xzv6ah3d
25 Nov 22
Definitive proxy
6:16am
8-K
EX-1.1
llh vmxz8d45mpbzz
9 Nov 22
Entry into a Material Definitive Agreement
4:50pm
424B5
gnn0s1rf2exyzz0c
9 Nov 22
Prospectus supplement for primary offering
4:29pm
8-K
EX-99.1
sd9potgd xa
8 Nov 22
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:19pm
10-Q
qp2ptfln 5e51o1q
8 Nov 22
Quarterly report
4:09pm
8-K
EX-1.1
khtefa9yaqo68
21 Oct 22
Entry into a Material Definitive Agreement
4:19pm
424B5
eyjn31lmjewhrf9fmb6
21 Oct 22
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
xhewjrxge
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
424B5
fs9kfch w4
13 Oct 22
Prospectus supplement for primary offering
4:56pm